Further National Microbiology Framework awards

RNS Number : 5136W

Yourgene Health PLC

26 April 2021

 

Yourgene Health plc

("Yourgene" or the "Group" or the "Company")

Further National Microbiology Framework contract awards

Successful tenders under Lots 2 & 3 valued at a total of £4bn

Yourgene one of only three companies to have been successfully awarded under all four lots

Manchester, UK - 26 April 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Public Health England ("PHE") has confirmed that Yourgene has been successful with its tenders under PHE's National Microbiology Framework for Lot 2 (Research and Development Goods andServices) and Lot 3 (Manufacturing, Product Development and Commercialisation).

Lot 2 is a £1.5bn Framework to be satisfied over a period of two years by multiple successful bidders, with 69 companies appointed to this lot. Similarly, Lot 3 is also a £2.5bn Framework to be satisfied over two years, but with only 9 suppliers appointed to this lot.

PHE's National Microbiology Framework appoints suppliers to framework agreements for four lots. Yourgene has now been successful in all four of these lots and is one of only three companies to do so. The lots are summarised below:

	Value	Duration
Lot 1: Diagnostic Goods and Services	£3bn	4yrs
Lot 2: Research and Development Goods and Services	£1.5bn	2yrs
Lot 3: Manufacturing, Product Development and Commercialisation	£2.5bn	2yrs
Lot 4: Clinical Laboratory Diagnostic Testing Services	£15bn	2yrs

Yourgene will be able to offer its Clarigene ®   SARS-CoV-2 PCR assay and associated Manchester-based clinical laboratory testing services under the National Microbiology Framework Agreement , as well as other testing or test development services.

Whilst the Framework Agreement is not exclusive to Yourgene, or a guarantee of orders, it does allow participating public health authorities across the UK to issue call-off contracts to procure goods and testing services from Yourgene, amongst other providers, going forward.

Lyn Rees, CEO of Yourgene commented:

"We are delighted with the successful tender award under both Lot 2 and 3 of the Microbiology Framework, alongside the previous awards. I can only reiterate that this is a testament to the quality and credibility of our accredited lab based COVID testing services.

"Over the last year we have built up an infectious disease business with an impressive testing capacity and a best-in-class product, and have done so without taking our focus away from our core business. We are now well positioned to compete for the next wave of contracts under this framework, particularly as one of only three companies successful in all four lots. We believe this has been the right approach to deliver value to our shareholders as we continue to deliver year-on-year revenue growth and position ourselves strongly in both the private and Government testing markets over the next two years. As and when we secure future call-off contracts under these framework agreements we will provide further updates."

This announcement contains inside information for the purposes of UK Market Abuse Regulation. The Directors of the Company take responsibility for this announcement.

Yourgene Health plc Lyn Rees, Chief Executive Officer		Tel: [phone] [e-mail]
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD)		Tel: [phone]
Liam Murray / James Caithie / Ludovico Lazzaretti
N+1 Singer (Joint Corporate Broker)		Tel: [phone]
Aubrey Powell / Tom Salvesen / George Tzimas
Stifel Nicolaus Europe Limited (Joint Corporate Broker)		Tel: [phone]
Nicholas Moore / Matthew Blawat / Ben Maddison
Walbrook PR Ltd (Media and Investor Relations)	Tel: [phone] or  [e-mail]
Paul McManus / Lianne Cawthorne		Mob: [phone] / Mob: [phone]

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

 

END

 

 

MSCFELLLFZLXBBL